Kravis Henry R's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed May 14, 2025
- Accession no.
- 0001140361-25-019003
- Filed
- May 14, 2025, 5:24 PM ET
- Trade date
- May 12, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $205.2M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kravis Henry RCIK 0001081714 | 10% Owner |
| Roberts George RCIK 0001081715 | 10% Owner |
| KKR & Co. Inc.CIK 0001404912 | 10% Owner |
| KKR Management LLPCIK 0001472694 | 10% Owner |
| KKR Group Partnership L.P.CIK 0001472698 | 10% Owner |
| KKR Group Holdings Corp.CIK 0001743754 | 10% Owner |
| KKR Genetic Disorder L.P.CIK 0001780408 | 10% Owner |
| KKR Genetic Disorder GP LLCCIK 0001780428 | 10% Owner |
| KKR Group Co. Inc.CIK 0001932162 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 12, 2025 | Common Stock | SSaleDisposed | −6,000,000 | $34.20F1 | −$205,200,000 | 13,260,971 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects the sale of 6,000,000 shares of common stock of BridgeBio Pharma, Inc. (the "Issuer"), par value $0.001 per share (the "Common Stock"), by KKR Genetic Disorder L.P. in a block sale at a price per share of $34.20 pursuant to Rule 144 of the Securities Act of 1933, as amended.
Referenced by the price of 1 transaction in Table I.